IP Library Assignment 017468/0289
Patent Assignment
Reel/Frame 017468/0289

Change of Name

Recorded: 2006-03-29 Pages: 11
Assignor
BIOGEN, INC.
Executed: 2003-11-13
Assignee
BIOGEN IDEC MA INC.
14 CAMBRIDGE CENTER, CAMBRIDGE, MASSACHUSETTS, 02142
Covered Properties (21)
Dna Sequences, Recombinant Dna Molecules and Processes for Producing Lymphocyte Function Associated Antigen-3
Patent: 4,956,281 →
Application: 07/057,615 →
CD2-Binding Domain of Lymphocyte Function Associated Antigen 3 (Lfa-3)
Application: 07/667,971 →
CD2-Binding Domain of Lymphocyte Function Associated Antigen 3 (Lfa-3)
Application: 07/770,967 →
Method of Prophylaxis or Treatment of Antigen Presenting Cell Driven Skin Conditions Using Inhibitors of the CD2/Lfa-3 Interaction
Application: 07/770,969 →
Method of Prophylaxis or Treatment of Antigen Presenting Cell Driven Skin Conditions Using Inhibitors of the CD2/Lfa-3 Interaction
Application: 07/862,022 →
CD2-Binding Domain of Lymphocyte Function Associated Antigen 3
Patent: 5,547,853 →
Application: 07/940,861 →
Methods of Inhibiting T-Cell Dependent Proliferation of Peripheral Blood Lymphocytes Using the CD2-Binding Domain of Lymphocyte Function Assoiciated Antigen 3
Patent: 5,728,677 →
Application: 08/459,512 →
CD2-Binding Domain of Lymphocyte Function Associated Antigen 3
Patent: 5,914,111 →
Application: 08/459,657 →
Method of Using CD2 Binding Domain of Lymphocyte Function Associated Antigen 3 to Initiate T Cell Activation.
Patent: 5,928,643 →
Application: 08/460,132 →
Method of Prophylaxis or Treatment of Antigen Presenting Cell Driven Skin Conditions Using Inhibitors of the CD2/Lfa-3 Interaction
Patent: 6,162,432 →
Application: 08/466,465 →
Method of Prophylaxis or Treatment of Antigen Presenting Cell Driven Skin Conditions Using Inhibitors of the CD2/Lfa-3 Interaction
Patent: 6,764,681 →
Application: 09/730,465 →
Publication: US 2002/0009449
Method of modulating memory effector T-cells and compositions
Application: 09/796,033 →
Publication: US 2002/0009446
Methods for treating or preventing skin disorders using CD2-binding agents
Application: 10/329,599 →
Publication: US 2003/0185824
Method for Treating or Preventing Sclerotic Disorders Using Cd-2 Binding Agents
Patent: 7,858,095 →
Application: 10/484,329 →
Publication: US 2004/0265305
Methods of Treating Skin Conditions Using Inhibitors of the CD2/Lfa-3 Interaction
Patent: 7,323,171 →
Application: 10/778,373 →
Publication: US 2004/0136987
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
Application: 11/282,853 →
Publication: US 2006/0084107
Methods for treating or preventing skin disorders using CD2-binding agents
Application: 11/312,627 →
Publication: US 2007/0031443
Method of Modulating Memory Effector T-Cells and Compositions
Application: 60/098,456 →
Methods for treating or preventing skin conditions using CD2-binding agents
Application: 60/265,964 →
Methods for treating or preventing sclerotic disorders using CD2-binding agents
Application: 60/307,688 →
Methods for treating or preventing sclerotic disorders using CD2-binding agents
Application: 60/382,459 →
Related Assignments (5)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name Apr 15, 2004
From: BIOGEN IDEC MA, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 014520/0982 →
Change of Name Apr 15, 2004
From: BIOGEN, INC.
To: BIOGEN IDEC MA, INC.
Reel/Frame 014532/0091 →
Assignment of Assignor's Interest Mar 24, 2006
From: VAISHNAW, AKSHAY K.
To: BIOGEN, INC.
Reel/Frame 017377/0709 →
Assignment of Assignor's Interest May 9, 2006
From: BIOGEN IDEC MA INC.
To: ASTELLAS US LLC
Reel/Frame 017596/0467 →
Assignment of Assignor's Interest Feb 16, 2007
From: MAGILAVY, DANIEL
To: ASTELLAS US LLC
Reel/Frame 018900/0253 →